CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
about
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's DiseaseModelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT scoreMultiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson diseaseStructure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology.A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.Proteomic studies associated with Parkinson's disease.Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity.Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression?Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis.Biomarker Research in Parkinson's Disease Using Metabolite Profiling.Parkinson's Disease: Assay of Phosphorylated α-Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma.Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels.Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?Assessments of plasma ghrelin levels in the early stages of parkinson's disease.Combining clinical and biofluid markers for early Parkinson's disease detection.Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease.Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?The Luxembourg Parkinson's Study: A Comprehensive Approach for Stratification and Early DiagnosisSerum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure
P2860
Q26744782-52E6046D-2E0C-4E22-B38F-D0632F522C4CQ29048624-55094C7A-947D-44A2-8EAE-94C193987AFFQ33698810-5BBA49B2-0FC9-4E26-BA89-9FDF3DCC77CEQ33701172-DE5769FA-075B-4BC5-AB78-5B9000DC3DC1Q33754677-DBCAB664-E592-4824-B5DD-9E15887BBAF9Q37629836-245DBB98-12FB-442C-A64D-D8F812ED358BQ38653383-466B0ED2-FA38-4E99-8FBE-BB0D4FC61935Q38761399-54DBF473-1CF9-413B-933C-7D26B85C0574Q38761409-EA8C3B91-B163-4814-A3F9-CE4CA8EB7A6FQ38792540-F84E4061-EBF1-4BC7-8B82-E4F1E7399DCDQ38889950-E8F955F0-180D-4520-9978-C8937CDD58A3Q39010887-7BE00D86-8DC7-4D72-9487-65741EDF3EFFQ39149219-6F3B0DC7-5CDE-4FBC-9DA2-546AD783C718Q39366291-53D716F0-D29F-4080-9DF2-B52D5A71E989Q40053985-31BEDE44-1CB6-44AA-9A98-366BFA623872Q41666702-D94F0327-109A-4D5B-8D5A-71D6ADE04C93Q41817806-35553964-1670-4ADC-95F8-7BF0F5D6E470Q45915163-3F8B39CE-9E81-4599-92A2-CACAFC3A3EFDQ46012657-E18E302B-BF2A-4EEC-B372-6DFF1BF45638Q47587631-C6876FD6-C3D5-4406-8744-BC16D5BC17D8Q47657093-55D75F44-BED4-45F1-B30D-E5991F5617CAQ47990737-5F5911C0-2841-4DA5-B977-262A82CF418AQ48129130-6B896704-A31A-4515-9DFA-12F33F828514Q48623727-DCB00C7C-D275-428E-A885-2ECED0A69451Q49202410-465BDD34-AF0D-48A0-BEE4-5086C95AE5F6Q50506611-B4BD3642-F358-43DB-ABBB-52B39A46C441Q51298413-D134729E-FE41-4C36-8009-3E354D7A045BQ58585963-9AAE8BFE-C029-4EA9-81CA-12B1EBB58010Q58699032-62C4C8D1-A3F2-40F5-9000-4C3A584A068BQ59137487-3AC21B80-1B02-4052-A5EC-02253E9BD36F
P2860
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CSF biomarkers associated with ...... sion Markers Initiative study.
@en
CSF biomarkers associated with ...... sion Markers Initiative study.
@nl
type
label
CSF biomarkers associated with ...... sion Markers Initiative study.
@en
CSF biomarkers associated with ...... sion Markers Initiative study.
@nl
prefLabel
CSF biomarkers associated with ...... sion Markers Initiative study.
@en
CSF biomarkers associated with ...... sion Markers Initiative study.
@nl
P2093
P2860
P50
P1476
CSF biomarkers associated with ...... sion Markers Initiative study.
@en
P2093
Alice S Chen-Plotkin
Chelsea Caspell-Garcia
Christopher S Coffey
Danna Jennings
David J Irwin
Douglas R Galasko
Ju-Hee Kang
Kenneth Marek
Leslie M Shaw
Mark Frasier
P2860
P2888
P304
P356
10.1007/S00401-016-1552-2
P50
P577
2016-03-28T00:00:00Z